Teva Pharmaceutical Industries (TEVA) to Release Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is set to release its earnings data before the market opens on Wednesday, May 8th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.49 per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Teva Pharmaceutical Industries Stock Up 0.5 %

Shares of NYSE TEVA opened at $14.06 on Tuesday. The firm’s 50-day moving average price is $13.63 and its 200-day moving average price is $11.65. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. The stock has a market capitalization of $15.76 billion, a price-to-earnings ratio of -29.90, a P/E/G ratio of 1.67 and a beta of 1.04. Teva Pharmaceutical Industries has a 12-month low of $7.09 and a 12-month high of $14.47.

Insider Activity at Teva Pharmaceutical Industries

In related news, CEO Richard D. Francis sold 74,530 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the sale, the chief executive officer now owns 87,125 shares in the company, valued at $1,145,693.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, VP Eric Drape sold 173,261 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $13.05, for a total value of $2,261,056.05. Following the sale, the vice president now owns 1 shares in the company, valued at $13.05. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the completion of the sale, the chief executive officer now owns 87,125 shares in the company, valued at approximately $1,145,693.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 358,972 shares of company stock worth $4,739,820. 0.55% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on TEVA shares. Jefferies Financial Group upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and upped their price target for the company from $10.00 to $14.00 in a report on Tuesday, January 23rd. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $12.00 to $19.00 in a research note on Monday, February 12th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research note on Friday, March 8th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.